Zobrazeno 91 - 100
of 2 141
pro vyhledávání: ''
Autor:
Kosj Yamoah, Elai Davicioni, Amparo Serna, Shivanshu Awasthi, Adriana C. Vidal, R. Jeffrey Karnes, Raavi Gupta, Sungyong You, David J. Einstein, Kevin H. Kensler, Julieta Abraham-Miranda, Michael R. Freeman, Jong Y. Park, Priti Lal, John L. Cleveland, Timothy R. Rebbeck, Steven P. Balk, Anders Berglund, Yang Liu, Bruce J. Trock, Robert B. Den, Robert J. Rounbehler, Stephen J. Freedland, Joshua D. Campbell, Eric A. Klein
Publikováno v:
Clin Cancer Res
Purpose: The role of immune-oncologic mechanisms of racial disparities in prostate cancer remains understudied. Limited research exists to evaluate the molecular underpinnings of immune differences in African American men (AAM) and European American
Autor:
Yuhe Xia, Judy Zhong, Douglas Donnelly, Iman Osman, David L. Rimm, Lee Wheless, Douglas B. Johnson, Paul Johannet, Sofia Nomikou, James R. Patrinely, George Jour, Nicolas Coudray, Jeffrey S. Weber, Aristotelis Tsirigos, Irineu Illa-Bochaca, Anna C. Pavlick
Publikováno v:
Clin Cancer Res
Purpose: Several biomarkers of response to immune checkpoint inhibitors (ICI) show potential but are not yet scalable to the clinic. We developed a pipeline that integrates deep learning on histology specimens with clinical data to predict ICI respon
Autor:
Nobuhiro Kado, Yoshimi Kiyozumi, Ken Yamaguchi, Satomi Higashigawa, Takuma Oishi, Yasue Horiuchi, Keiichi Ohshima, Kenichi Urakami, Takeshi Nagashima, Hiroyuki Matsubayashi, Yasuyuki Hirashima, Sumiko Ohnami, Akio Shiomi
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 30:166-174
Background: Tumor mutation burden (TMB) is the total exonic mutation count per megabase of tumor DNA. Recent advances in precision medicine occasionally detect Lynch syndrome (LS) by germline sequencing for mismatch-repair (g.MMR) genes but not using
Autor:
Pasi A. Jänne, Christie J. Lau, Erin M. Bertino, D. Ross Camidge, Lynette M. Sholl, Jeffrey A. Moscow, Geoffrey R. Oxnard, Zofia Piotrowska, Jyoti Malhotra, Jill M. Kolesar, Christine L. Hann, Thomas E. Stinchcombe, Liza C. Villaruz, Geoffrey I. Shapiro, Sarah E. Clifford, Alona Muzikansky, Cloud P. Paweletz, Ryan D. Gentzler, Eric B. Haura, Naoko Takebe
Publikováno v:
Clin Cancer Res
Purpose: Osimertinib is an effective therapy in EGFR-mutant non–small cell lung cancer (NSCLC), but resistance invariably develops. Navitoclax is an oral inhibitor of BCL-2/BCL-xL that has exhibited synergy with osimertinib in preclinical models of
Autor:
Thanh P. Ho, Eric C. Polley, Robert R. McWilliams, William R. Bamlet, Steven N. Hart, Kari G. Rabe, Nicholas J. Boddicker, Pashtoon Murtaza Kasi, Fergus J. Couch, Chunling Hu, Siddhartha Yadav, Kun Y. Lee, Gloria M. Petersen, Tricia Lindstrom, Rohan Gnanaolivu
Publikováno v:
Clin Cancer Res
Purpose:To compare the clinical characteristics and overall survival (OS) of germline mutation carriers in homologous recombination repair (HRR) genes and noncarriers with pancreatic ductal adenocarcinoma (PDAC).Experimental Design:Germline DNA from
Autor:
Tatsuo Ichinohe, Yoshiko Atsuta, Makoto Onizuka, Yuta Katayama, Takaaki Konuma, Ken-ichi Matsuoka, Ken Ishiyama, Takehiko Mori, Aiko Igarashi, Takahiro Fukuda, Yukiyasu Ozawa, Naoyuki Uchida, Yasunori Ueda
Publikováno v:
Clinical Cancer Research. 26:6483-6493
Purpose: Potent graft-versus-tumor (GVT) effects associated with graft-versus-host disease (GVHD) might be dependent on hematologic disease type and status. However, the data regarding the impact of GVHD on transplant outcomes for patients with myelo
Autor:
Anthony Serritella, Bryan Peterson, Stephanie Moya, Yan Wang, Natalie Reizine, Joseph Thomas, Carol Tan, Katherine I. Zhou, Daniel V.T. Catenacci
Publikováno v:
Clin Cancer Res
Purpose: Intrapatient heterogeneity of programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB) in gastroesophageal adenocarcinoma (GEA) could influence their roles as predictive biomarkers for response to immune checkpoint inhi
Autor:
Lawrence H. Einhorn, Darren R. Feldman, M. Eileen Dolan, Omar El-Charif, Christian Kollmannsberger, Chunkit Fung, David J. Vaughn, Robert J. Hamilton, Heather E. Wheeler, Lois B. Travis, Matthew Trendowski
Publikováno v:
Clin Cancer Res
Purpose: Cisplatin is a first-line chemotherapeutic for many cancers, but causes neurotoxicity including hearing loss, tinnitus, and peripheral sensory neuropathy. However, no study has comprehensively characterized risk factors for developing multip
Autor:
Ilker Y. Eyüpoglu, Klaus Podar, Andreas Stadlbauer, Franz Marhold, Melitta Kitzwögerer, Thomas M. Kinfe, Stefan Oberndorfer, Gertraud Heinz, Max Zimmermann, Michael Buchfelder
Publikováno v:
Clinical Cancer Research. 27:1641-1649
Purpose: Insufficient control of infiltrative glioblastoma (GBM) cells is a major cause of treatment failure and tumor recurrence. Hence, detailed insights into pathophysiologic changes that precede GBM recurrence are needed to develop more precise n
Autor:
Joyce Cheng, Whitney S. Helms, Adnan A. Jaigirdar, Marc R. Theoret, Kwadwo Korsah, Atiqur Rahman, Julia A. Beaver, Rajiv Agarwal, Salaheldin S. Hamed, Hong Zhao, Harpreet Singh, Anwar Goheer, Yangbing Li, Jiang Liu, Sonia Singh, John K. Leighton, Xing Wang, Richard Pazdur, Shenghui Tang, Flora Mulkey, Rajan Pragani
Publikováno v:
Clin Cancer Res
On June 15, 2020, the FDA granted accelerated approval to lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Approval was granted on the ba